Latest Period
Q1 2026
Security Snapshot
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) Institutional Ownership
CUSIP: 29842P105
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
53
Shares (Excl. Options)
21,984,367
Price
$7.24
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value
- Symbol
- EPRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 21,984,367
- Total 13F value
- $156,495,266
- Portfolio coverage rank
- 0%
- Share change
- +8,148,073
- Value change
- +$58,795,150
- Number of holders
- 53
- Shares outstanding
- 52,146,078
- SEC-reported price per share
- $7.38
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 29842P105.
- 53 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 35 to 53 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $104,211,571 to $156,495,266.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 53 institutions filings for Q1 2026.
Security key
29842P105
Latest holder period
Q1 2026
13F holders
53
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
EPRX full holder history
EUPRAXIA PHARMACEUTICALS INC. SEC filings
EUPRAXIA PHARMACEUTICALS INC. company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29842P105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
EPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Freedman Joseph S. | 9% | -12% | $47,037,881 | +$2,495,500 | 5,843,215 | +5.6% | Joseph S. Freedman | 13 Mar 2026 |
| Beutel, Goodman & Co Ltd. | 8% | $23,947,504 | 4,058,899 | Beutel, Goodman & Co Ltd. | 30 Sep 2025 | |||
| MANCHESTER MANAGEMENT CO LLC | 7.7% | -17% | $28,829,481 | -$6,384,994 | 4,015,248 | -18% | Morgan C. Frank | 31 Mar 2026 |
| DISBROW ROBERT | 7% | $21,052,085 | 3,568,150 | Robert Disbrow | 30 Sep 2025 |
As of 31 Mar 2026, 53 institutional investors reported holding 21,984,367 shares of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX). This represents 42% of the company’s total 52,146,078 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
40%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 7% | 3,666,465 | -1.2% | 0.18% | $26,377,000 |
| Affinity Asset Advisors, LLC | 3% | 1,589,005 | +430% | 0.67% | $11,504,396 |
| Vivo Capital, LLC | 2.6% | 1,350,000 | 0% | 0.81% | $9,774,000 |
| Balyasny Asset Management L.P. | 2.6% | 1,350,000 | 0% | 0.02% | $9,774,000 |
| SCOTIA CAPITAL INC. | 2.6% | 1,342,178 | +4.4% | 0.03% | $7,244,058 |
| Ikarian Capital, LLC | 2.3% | 1,214,741 | +99% | 1.3% | $8,794,726 |
| GREAT POINT PARTNERS LLC | 2.3% | 1,200,000 | 0% | 2.1% | $8,688,000 |
| Point72 Asset Management, L.P. | 1.9% | 967,575 | +36% | 0.01% | $7,005,402 |
| UBS Group AG | 1.5% | 762,635 | +247% | 0% | $5,521,478 |
| Redmile Group, LLC | 1.3% | 700,000 | 0.34% | $5,068,000 | |
| Rubric Capital Management LP | 1.3% | 691,170 | 0.06% | $5,004,071 | |
| Squadron Capital Management LLC | 1.3% | 680,000 | +36% | 2% | $4,923,200 |
| Ally Bridge Group (NY) LLC | 1.3% | 660,375 | +66% | 4.7% | $4,781,115 |
| PFM Health Sciences, LP | 1% | 540,871 | 0.41% | $3,915,906 | |
| AMERIPRISE FINANCIAL INC | 1% | 524,257 | 0% | $3,795,620 | |
| Woodline Partners LP | 0.84% | 440,551 | 0.01% | $3,189,589 | |
| Seven Fleet Capital Management LP | 0.83% | 433,515 | 0.99% | $3,138,649 | |
| Alyeska Investment Group, L.P. | 0.72% | 375,000 | 0.01% | $2,715,000 | |
| Velan Capital Investment Management LP | 0.68% | 352,000 | 0% | 1.6% | $2,548,480 |
| SummitTX Capital, L.P. | 0.63% | 327,997 | +86% | 0.08% | $2,374,698 |
| Aisling Capital Management LP | 0.62% | 325,000 | 0.49% | $2,353,000 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.62% | 323,843 | +107% | 0.06% | $2,344,623 |
| DV Trading LLC | 0.53% | 276,000 | 0.18% | $1,998,240 | |
| BANK OF AMERICA CORP /DE/ | 0.51% | 268,221 | +5.9% | 0% | $1,941,920 |
| ROYAL BANK OF CANADA | 0.5% | 261,376 | +33% | 0% | $1,893,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 21,984,367 | $156,495,266 | +$58,795,150 | $7.24 | 53 |
| 2025 Q4 | 13,830,451 | $104,211,571 | +$5,872,102 | $7.55 | 35 |
| 2025 Q3 | 12,813,323 | $75,287,324 | +$63,953,992 | $5.90 | 27 |
| 2025 Q2 | 1,970,076 | $10,889,810 | -$1,049,985 | $5.76 | 14 |
| 2025 Q1 | 2,167,593 | $7,087,336 | +$1,118,946 | $3.28 | 11 |
| 2024 Q4 | 1,826,270 | $5,634,759 | +$50,501 | $3.17 | 9 |
| 2024 Q3 | 1,798,968 | $4,545,745 | +$185,000 | $2.63 | 8 |
| 2024 Q2 | 1,727,190 | $4,433,025 | +$4,433,025 | $2.58 | 8 |